← Back to Search


Angiomammography for Breast Cancer Response Prediction

Research Sponsored by CHU de Quebec-Universite Laval
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
No evidence of distant metastasis
Histologically proven breast cancer by large gauge needle
Screening 3 weeks
Treatment Varies
Follow Up cycle 2 (each cycle being 21 days), i.e., after the chemotherapy on day 1 of cycle 2 and before cycle 3.
Awards & highlights

Study Summary

This trial is looking at whether a less expensive and more readily available diagnostic modality, namely CESM, is as effective as MRI in predicting the response of a malignant breast tumor to neoadjuvant chemotherapy and the chances of achieving a pCR.

Who is the study for?
This trial is for women over 18 with breast cancer that hasn't spread far (no distant metastasis), measurable by examination. They must be undergoing neoadjuvant chemotherapy, possibly with additional targeted therapy. Exclusions include pregnancy, allergies to contrast dye, MRI contraindications, overt hyperthyroidism, and significant kidney failure.Check my eligibility
What is being tested?
The study compares two imaging techniques—CESM and MRI—to see which better predicts the absence of invasive cancer cells in the breast and lymph nodes after early rounds of chemotherapy. This could help switch treatments sooner for those not responding well.See study design
What are the potential side effects?
Potential side effects may relate to the use of contrast dyes during imaging tests such as allergic reactions or kidney issues. The MRI might not be suitable for people with certain implants or claustrophobia.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
My cancer has not spread to distant parts of my body.
My breast cancer was confirmed with a biopsy.
My breast tumor can be felt and measured by a doctor.


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~cycle 2 (each cycle being 21 days), i.e., after the chemotherapy on day 1 of cycle 2 and before cycle 3.
This trial's timeline: 3 weeks for screening, Varies for treatment, and cycle 2 (each cycle being 21 days), i.e., after the chemotherapy on day 1 of cycle 2 and before cycle 3. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of patients with a pCR accoreding to angiomammography, based on a 50% reduction in lesion size at angiomammography

Trial Design

1Treatment groups
Experimental Treatment
Group I: Neoadjuvant chemotherapyExperimental Treatment1 Intervention

Find a Location

Who is running the clinical trial?

CHU de Quebec-Universite LavalLead Sponsor
167 Previous Clinical Trials
107,057 Total Patients Enrolled
4 Trials studying Breast Cancer
1,097 Patients Enrolled for Breast Cancer

Media Library

Neoadjuvant Chemotherapy (Chemotherapy) Clinical Trial Eligibility Overview. Trial Name: NCT05402930 — N/A
Breast Cancer Research Study Groups: Neoadjuvant chemotherapy
Breast Cancer Clinical Trial 2023: Neoadjuvant Chemotherapy Highlights & Side Effects. Trial Name: NCT05402930 — N/A
Neoadjuvant Chemotherapy (Chemotherapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05402930 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any remaining openings for participants in this trial?

"Affirmative. Clinicaltrials.gov maintains that this clinical trial, which was first posted on March 1st 2018, is currently recruiting patients from one location with a total of 100 participants needed."

Answered by AI

How many people are actively participating in this experiment?

"Affirmative, the available information from clinicaltrials.gov states that this experiment is actively recruiting volunteers. It was published on March 1st 2018 and updated June 10th 2022, seeking 100 individuals from one site."

Answered by AI
~10 spots leftby Dec 2024